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Abstract
Transport of iron to tissues is of vital importance. Remarkable advances have been made concerning the 
mechanisms involving iron metabolism after its absorption. Studies assessing cellular and mitochondrial 
iron metabolism have resulted in interesting findings. This review highlights the recent advances in the 
mechanisms involving transport and delivery of iron to tissues, cellular and mitochondrial iron metabolism, 
iron-related molecules, and mitochondrial disorders. (Turk J Hematol 2010; 27: 137-46)
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Özet
Demirin dokulara taşınması yaşamsal önem taşır. Demirin emiliminden sonraki metabolizmasıyla ilgi-
li büyük ilerlemeler kaydedilmiştir. Selüler ve mitokondriyal demir metabolizmasıyla ilgili araştırmalar 
ilginç sonuçlar vermektedir. Bu derleme demirin dokulara taşınması, verilmesi, hücresel ve mitokond-
riyal demir metabolizması, demirle ilişkili moleküller ve mitokondriyal hastalıklarla ilgili yeni gelişme-
leri vurgulamaktadır. (Turk J Hematol 2010; 27: 137-46)
Anahtar kelimeler: Demir, demir taşınımı, mitokondri, mitokondriyal demir
Geliş tarihi: 8 Şubat 2010    Kabul tarihi: 6 Nisan 2010
A current theme in the field of hematology as 
well as in other disciplines is the molecular mecha-
nisms concerning iron metabolism. Mechanisms 
involving absorption of iron by enterocytes has been 
reviewed elsewhere [1-3]. In this review, delivery of 
iron to tissues, mechanisms concerning cellular 
and mitochondrial iron metabolism, iron-related 
molecules, and mitochondrial disorders are pre-
sented (Table 1). 
Transport of iron in plasma
Binding to transferrin (Tf) is the first step in iron 
transport. Tf has high affinity for ferric iron; there-
fore, the oxidation of ferrous (Fe+2) to the ferric 
(Fe+3) form by hephaestin is an essential step for 
transport. Hephaestin is a ceruloplasmin homolog, 
and colocalizes with ferroportin at the basolateral 
membrane of enterocytes. The role of hephaestin in 
iron absorption was first shown in the sla (sex-linked anemia) mouse with moderate to severe 
microcytic hypochromic anemia [4,5]. Enterocytes 
of the sla mouse are able to absorb iron from 
lumen; however, there is a block in transport to 
blood due to defective hephaestin. Another mole-
cule that has a very important influence on iron 
absorption at this step is hepcidin. If total body iron 
is high, hepatic synthesis of hepcidin increases. 
Binding of hepcidin to ferroportin in its exterior seg-
ment causes upregulation of Janus kinase 2 [6,7]. 
Activation of Janus kinase 2 results in internaliza-
tion, ubiquitination and degradation of ferroportin, 
which results in decreased iron transfer to blood. 
Transferrin is the major protein that binds and 
delivers iron to tissues. It is member of a family of 
homologous transport proteins that includes lacto-
ferrin, ovotransferrin, and melanotransferrin. All of 
these proteins share the same structure. Due to a 
suggested ancestral gene duplication, N- and C- ter-
minals (lobes) of these proteins show approximate-
ly 40% sequence identity. These terminals are sepa-
rated by a short spacer sequence. Each of these two 
lobes (N- and C-) is divided into two equally sized 
domains: N1, N2 and C1, C2. Clefts between these 
domains are designed for transport of Fe+3; there-
fore, each Tf molecule can transport 2 iron mole-
cules [8,9]. Side chains of 1 asparagine, 2 tyrosines 
and 1 histidine provide 3 negative charges within the 
cleft matching 3 positive charges of Fe+3. Also, bind-
ing of CO2
3     
- ion is critical for the binding and release 
of Fe+3. Ferric iron and CO2
3     
- ion could not bind to Tf 
in the absence of the other. Conformation of the 
binding site is suitable with ferric iron through a 
delicate balance. Binding constant for Fe+3  is 
approximately 1020 whereas it is only 103 for 
Fe+2 [10]. Binding and release of iron result in con-
formational changes in the Tf molecule enabling 
rapid exchange [11]. 
Transferrin receptors
Transferrin receptor (TfR), the binding site of Tf 
on the cell, has two types; namely TfR1 and TfR2. 
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Table 1. Genetic and functional identification of some iron-related proteins
 OMIM#  Gene  Locus  Function  Reference
Hephaestin 300167  HEPH  Xq11-q12  Oxidizes  Fe+2 to Fe+3 4,  5
Hepcidin  606464  HAMP  19q13  Induces internalization, ubiquitination and degradation   6, 7
        of ferroportin via Janus kinase 2 
Transferrin  190000  TF  3q21  Transports iron from enterocyte to cells  8
Transferrin receptor 1 (CD71)  190010  TFR1  3q29  Transports Tf through the cell membrane  13
Transferrin receptor 2  604720  TFR2  7q22  Transports Tf through the cell membrane especially in hepatocytes 14
STEAP3  609671  STEAP3 (TSAP6)  2q14.2  Converts Fe+3 to Fe+2 in endosomes  22
IRP1  100880  IRP1 (ACO1)  9p22-p13  Bifunctional protein, acts as aconitase or iron response protein   28
        due to cellular iron levels 
IRP2  147582  IRP2 (IREB2)  15q25.1  Binds to IRE in low-iron conditions  29
MRCKα  603412  MRCKA  1q41-q42  Regulates Tf-vesicle movement through actin/myosin filament   30
        assembly in response to decreased intracellular iron level 
CDC14  603504  CDC14A  1p21  Operates in cell cycle, acts as a tumor suppressor  31
Poly r(C)-Binding Protein 1  601209  PCBP1  2p13-p12  Delivers iron from endosomes to ferritin  35
Mitoferrin  610387  MFRN  8p21  An iron importer on the inner membrane of the mitochondria  38
Frataxin  606829  FXN  9q13  Bifunctional mitochondrial protein that acts as a chaperone or   40
        stores iron due to cellular iron levels 
Mitochondrial ferritin  608847  FTMT  5q21.3  Stores iron in mitochondrial matrix  41
ATP-Binding Cassette, Subfamily  300135  ABCB7  Xq13.1-q13.3  Transports ISCs to cytoplasm, a putative role in heme synthesis   43, 44
B, Member 7 (ABCB7)        is also suggested 
ATP-Binding Cassette, Subfamily   605452  ABCB6  2q36  Transports porphyrin to mitochondria and functionally linked to  45, 46
B, Member 6 (ABCB6)         heme biosynthesis 
Glutaredoxin  609588  GLRX5  14q32  Required for ISC assembly   60
BCS1L  603647  BCS1L  2q33  A chaperone that facilitates insertion of Rieske Fe/S protein into   66
        mitochondrial respiratory chain complex III TfR1 has an extremely important role in embryo-
genesis; knockout embryos do not survive due to 
defective erythropoiesis and neurological develop-
ment [12,13]. However, other tissues are not affect-
ed in the absence of TfR1, which indicates addi-
tional mechanism(s) for iron transport in these 
cells. TfR1 is expressed in all tissues except mature 
erythrocytes. On the other hand, TfR2 is mainly 
expressed in the liver, normal erythroid precursors 
and some leukemic cells [14,15]. Although protein 
structures of TfR1 and TfR2 have a high degree of 
homology, their functions and regulation are not the 
same [16]. 
Expression of TfR1 is tightly regulated by cellular 
iron levels through HFE (hereditary hemochromato-
sis) protein. In normal conditions, HFE protein 
decreases the affinity of TfR1 for Tf by a magnitude 
of 10 to 50 [17]. Mutations in the HFE gene may alter 
the iron absorption and cause hemochromatosis 
phenotype. Nonetheless, cellular iron levels have 
no effect on the regulation of TfR2. Furthermore, 
TfR2 has no interaction with the HFE protein in con-
trast to TfR1. High levels of TfR2-mRNA expression 
in erythroid precursors and erythroleukemia cells 
point out that TfR2 expression is both cell-cycle and 
differentiation dependent [15]. Similar to TfR1, TfR2 
has high affinity for diferric Tf. TfR2-mediated endo-
cytosis of the Tf/iron complex is also the same as 
with TfR1 [18]. On the other hand, affinity of TfR2 for 
Tf is approximately 25-30-fold less than that of TfR1. 
Mutations in TfR2 cause a rare type of hereditary 
hemochromatosis (HH), namely HFE 3. A recent 
study in zebrafish embryos showed that TfR2 was 
required for hepcidin expression [19]. In summary, 
TfR2 senses the body iron status by sensing the Tf 
saturation. Consequently, it modulates hepcidin 
expression adjusted to the actual body iron level. 
Therefore, loss of TfR2 or its function results in fail-
ure to sense body iron status by hepatocytes, which 
causes increased hepcidin and iron deposition, 
especially in the liver [20].
Transfer of iron into cells
After binding of diferric Tf to TfR, the Tf/TfR com-
plex on the clathrin-coated cell membrane is inter-
nalized through a receptor-mediated endocytosis. 
Clathrin coat is needed for invagination of the cell 
membrane. Newly formed vesicles lose the clathrin 
coat and fuse with endosomes [21]. After formation 
of endosomes, the acidification process by means 
of an ATPase proton pump (pH 5.5-6) takes place in 
order to dissociate iron from Tf. A protein called 
STEAP3 (Six-Transmembrane Epithelial Antigen of 
Prostate 3), has been shown to convert Fe+3 to Fe+2 
in erythroid precursor cells [22]. An animal model 
revealed that STEAP3 is highly expressed in hema-
topoietic tissues, colocalizes with the Tf cycle endo-
some, and facilitates Tf-bound iron uptake. 
Moreover, mutations in the STEAP3 gene were 
found to be responsible for the iron deficiency ane-
mia in the mouse mutant nm1054. Homologs of this 
protein, STEAP1, 2 and 4, are expressed in hepato-
cytes as well as other tissues [23]. Free ferrous iron 
released from Tf in the endosome enters into cyto-
plasm via DMT1 on the endosomal membrane. 
Then, the endosome containing Tf and TfR fuses 
back to the plasma membrane. This recycling pro-
cess enables Tf and TfR to be used in new cycles. 
Hepatic iron uptake
Hepatic iron transport has different aspects com-
pared to the other cells [24]. Hepatocytes can 
acquire both transferrin-bound iron (TBI) and non-
transferrin-bound iron (NTBI) from plasma (Table 2). 
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Table 2. Hepatocyte uptake of iron-related proteins
Form of iron  Hepatic uptake mechanism  Entry into hepatocyte
TBI  TfR1- or TfR2-mediated endocytosis  Through DMT1 on endosomal membrane
  Direct uptake of iron after releasing from Tf on   Through DMT1, ZIP14 or calcium channels on
  hepatocyte surface  hepatocyte membrane
NTBI  Direct uptake of iron after releasing from carrier   Through DMT1, ZIP14 or calcium channels on
  molecule (mostly citrate) on hepatocyte surface  hepatocyte membrane
Ferritin  
Lactoferrin 
Specific receptor-mediated uptake  Through endocytosis 
 
Heme-hemopexin complex   
Hemoglobin-haptoglobin complex TBI uptake may occur through TfR-dependent or 
-independent mechanisms. As discussed above, both 
TfR1 and TfR2 operate in the uptake of TBI. In the 
process of TfR-independent delivery of Tf-bound iron, 
Tf releases iron at the hepatocyte surface. Following 
this step, a ferrireductase activity converts Fe+3  to 
Fe+2, which also takes place at the surface [25]. 
Afterwards, Fe+2 enters the cell via membrane 
transporters. The most common form of NTBI is 
iron citrate, usually increased in iron overload disor-
ders [26]. Iron citrate releases iron at the hepato-
cyte surface like TBI. Iron delivered by NTBI also 
enters hepatocytes via membrane transporters, 
especially DMT1 [27]. Other molecules transporting 
iron through the hepatocyte membrane are ZIP14 
and calcium channels.
There are some other iron-related proteins or 
complexes transported to hepatocytes by specific 
membrane receptors. These include ferritin, lactofer-
rin, heme-hemopexin complex, and hemoglobin-
haptoglobin complex. The fate of these molecules in 
hepatocytes following endocytosis may be different: 
iron and some proteins (i.e. ferritin) may reside in the 
hepatocyte, some proteins may go into degradation 
(i.e. ferritin, heme, hemoglobin, haptoglobin, lacto-
ferrin), whereas others may recycle back to the 
plasma (i.e. hemopexin, receptors of these proteins) 
or to bile (i.e. ferritin, hemoglobin) [24].
Molecular control of iron content in cells
The need for iron is different in different body 
cells. For example, cardiomyocytes, muscle cells 
and neurons require higher amounts of iron com-
pared to the other cells. Therefore, uptake of iron is 
individually regulated in each cell regardless of total 
body iron need. Important molecules concerning 
cellular iron uptake are iron-responsive proteins 
(IRP1 and IRP2) and iron-responsive elements 
(IRE). Two IRPs have been defined to date: IRP1 and 
IRP2 [28,29]. In iron-depleted conditions, IRP1 and 
2 bind to IREs of a number of molecules related to 
iron metabolism (Table 3). These molecules are 
assigned to iron uptake (TfR1, DMT1), utilization 
[5-aminolevulinate synthase (ALAS1) and erythroid 
ALAS (ALAS2)], storage (H- and L-ferritin) or export 
(ferroportin). Recent studies showed that at least 
two cell cycle-related molecules, MRCKα (myotonic 
dystrophy kinase-related Cdc42-binding kinase) and 
CDC14A (cell division cycle 14A), also bear IREs in 
their mRNA at the 3’ untranslated region (UTR). It has 
been suggested that MRCKα, a serine/threonine 
kinase, regulates Tf-vesicle movement through actin/
myosin filament assembly in response to decreased 
intracellular iron level. Supporting this suggestion, 
MRCKα-mRNA levels in various tissues strongly 
positively correlated with the level of TfR-mRNA lev-
els [30]. The second cell cycle-related molecule, 
CDC14A, is a phosphatase involved in the dephos-
phorylation of several critical cell cycle proteins and 
is suggested to act as a tumor suppressor [31]. 
Synthesis of IRPs is regulated by IRPs to maintain 
optimum iron levels in each cell. Depending on the 
location of IRE, the IRE/IRP interaction results in sta-
bilization or translational repression of mRNA [32]. 
During low-iron conditions, synthesis of both IRP1 
and IRP2 increases. Interaction of IRPs with IREs in 
the 3’ UTR of mRNA results in stabilization; therefore, 
increased expression of molecules such as TfR1 and 
DMT1. Meanwhile, interaction of IRPs with IREs in 
the 5’ UTR of mRNA results in translational repres-
sion; the expression of molecules such as ferritin, 
ferroportin, and ALAS2 will be suppressed. During 
high-iron levels, both IRP1 and IRP2 lose their affinity 
for IRE. As a result, mRNAs bearing IRE in the 5’ UTR 
stabilize and expression of molecules such as ferritin, 
ferroportin, and ALAS2 increases whereas synthesis 
of TfR1 and DMT1 decreases. IRP1 is a bifunctional 
protein that binds iron-sulfur clusters (ISC) in case of 
high intracellular iron. After binding ISC [4Fe-4S], 
IRP1 functions as aconitase, and loses its IRE-related 
functions. However, the high intracellular iron levels 
do not cause a conformational change but rather 
cause degradation of IRP2. 
Erythroid cells require more iron than any other 
cell in the body. Therefore, these cells need specific 
adaptation mechanism(s) for high iron influx. A 
recent study revealed that terminal erythropoiesis 
caused a switch of regulation to a different mode in 
the IRP/IRE system [33]. Since committed erythro-
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Table 3. Some iron-related molecules containing IREs on their mRNA 
Molecule  IRE localization on mRNA  Function
TfR1 3’UTR  Iron  uptake
DMT1 3’UTR  Iron  uptake
Ferroportin 5’UTR  Iron  export
H- and L-ferritin  5’UTR  Iron storage
ALAS1 and ALAS2  5’UTR  Iron utilization
MRCKα  3’UTR  Tf vesicle movement
CDC14A 3’UTR  Tumor  suppressorblasts need much more iron than any other cell, they 
should maintain high TfR1 expression despite high 
intracellular iron levels. In this context, the erythroid 
IRP/IRE system should sense a low-iron state despite 
increased cytosolic iron. Furthermore, although both 
ferritin- and ALAS2-mRNAs bear IRE on their 5’ UTR, 
strong inhibition of ferritin-mRNA translation and effi-
cient ALAS2-mRNA translation have been observed 
in differentiating, iron-rich erythroblasts. Another 
conflicting data regarding IRE/IRP regulation is of fer-
roportin. Ferroportin-mRNA also bears IRE on its 5’ 
UTR. Therefore, during low-iron conditions, mRNA 
stability of ferroportin should decrease in all cells. 
However, this is not the case for duodenal absorptive 
cells and erythroid precursors. During low-iron con-
ditions, increased absorption of iron by enterocytes 
and release to blood via ferroportin is a physiologi-
cally relevant way. A very recent study documented 
that duodenal epithelial and erythroid precursor 
cells utilize an alternative upstream promoter to 
express a ferroportin transcript, ferroportin1B, 
which lacks the IRE and is not repressed in iron-
deficient conditions [34]. The identification of fer-
roportin1B may explain how high ferroportin expres-
sion is possible in duodenal epithelial and erythroid 
precursor cells during high intracellular iron levels. 
This study strongly suggests that different regulatory 
systems operate influx of iron into different cells. 
Mitochondrial iron metabolism
After entering from the endosome to cytoplasm, 
iron can be stored within ferritin or it can be used 
for cellular reactions. A newly discovered protein, 
PCBP1 [Poly r(C)-Binding Protein 1], has been 
reported to transfer iron from the endosome to fer-
ritin [35]. Although the exact mechanism of iron 
transport to mitochondria is not well defined, iron 
can also enter the mitochondria. A recent report 
defined a new way, namely “kiss and run” [36]. It 
was suggested that delivery of iron to mitochondria 
happens directly from iron-containing endosomes 
bypassing the cytoplasm. Molecules, including iron, 
cross the mitochondrial outer membrane via a large 
diameter voltage-dependent anion channel called 
porin [37]. Transport of iron through the inner mito-
chondrial membrane occurs with the aid of mitofer-
rin, a special carrier. Mutation in the mitoferrin gene 
has been described in a zebrafish mutant that 
caused profound hypochromic anemia and ery-
throid maturation arrest owing to defects in mito-
chondrial iron uptake [38]. After its transport into 
mitochondria, iron can be stored or used for vital 
reactions. Two important iron-related reactions that 
happen within mitochondria are heme synthesis 
and ISC biogenesis [39]. Iron in the mitochondrial 
matrix is in potentially redox-active ferrous (Fe+2) 
form. Therefore, tight control of iron influx and 
maintenance in bound-form is mandatory to 
achieve low toxic iron levels in the mitochondrial 
matrix. Two newly described proteins store iron 
within the matrix: frataxin (FXN) and mitochondrial 
ferritin. FXN is a bifunctional protein like IRP1 [40]. 
It works as a Fe+2 chaperone for metabolic actions 
when mitochondrial iron is limited. When iron is in 
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Table 4. Some disorders related to mitochondrial iron metabolism
Disease   OMIM#  Inheritance  Related gene locus  Related molecular defect  Clinical features
Friedreich ataxia  229300  Autosomal  9q13, 9p23-p11  Expansion of GAA triplet   Progressive ataxia, cardiomyopathy,
    recessive    repeats in intron 1 (97%) or  skeletal deformities, and
        point mutations in FXN gene  impaired glucose tolerance or 
         diabetes  mellitus
X-linked sideroblastic anemia  300751  X- linked  Xp11.21  Mutation in ALAS2 gene  Hypochromic microcytic anemia,
    recessive      variable response to pyridoxine treatment 
Pyridoxine-unresponsive   205950  Autosomal  14q32, 3p22.1  Mutation in GLRX5 gene  Severe microcytic anemia, jaundice,
sideroblastic anemia due to     recessive      hepatosplenomegaly, iron overload,
GLRX5 mutation          ringed sideroblasts, and cirrhosis
X-linked sideroblastic anemia  301310  X- linked  Xq13.1-q13.3  Mutation in mitochondrial  Hypochromic microcytic anemia, early
with ataxia    recessive    ABCB7 gene  onset nonprogressive ataxia
Myopathy associated with   255125  Autosomal  12q24.1  Mutation in ISCU1 gene  Early fatigue, dyspnea, and palpitations
ISCU1 defect    recessive      followed by hard and tender muscles and
         muscle  cramps 
GRACILE syndrome  603358  Autosomal   2q33  Mutation in BCS1L gene  Growth retardation, amino aciduria,
    recessive      cholestasis, iron overload, lactic acidosis, 
          and early deathexcess, it works as a storage compartment forming 
ferrihydrite. The mitochondrial ferritin precursor 
protein is coded by an unusual intronless gene and 
targeted to mitochondria. Within mitochondria, this 
precursor is processed to a smaller protein, mito-
chondrial ferritin. It is remarkably similar to H-ferritin 
that assembles into typical ferritin shells within 
mitochondria and has ferroxidase activity [41]. 
Immunohistochemical analysis showed that eryth-
roblasts of subjects with impaired heme synthesis 
had high amounts of mitochondrial ferritin accumu-
lation. In pathological conditions, it can be easily 
detected as “ringed sideroblast” [42]. 
One of the main functions of mitochondria is ISC 
biosynthesis. These clusters are cofactors of several 
proteins including electron transport, Krebs cycle, reg-
ulation of gene expression, and redox reactions [39]. 
Iron sulfur clusters have also been shown in cyto-
plasm within IRP1 and in the nucleus within an 
enzyme that is involved in base excision repair. After 
synthesis within mitochondria, ISCs are transported 
to cytoplasm through mitochondrial inner membrane 
channels by a specific carrier, ABCB7 (ATP-Binding 
Cassette, Subfamily B, Member 7) [43]. ABCB7 also 
interacts with ferrochelatase, suggesting a putative 
role in heme metabolism [44]. The mitochondrion 
is a major site for heme synthesis. Out of 8 steps in 
heme biosynthesis, 4 steps, including the first rate-
limiting step of the pathway, take place within mito-
chondria. This step involves condensation of succi-
nyl CoA and glycine to delta-aminolevulinate cata-
lyzed by delta-ALAS. There are 2 types of ALAS: 
ALAS1 and ALAS2 (erythroid ALAS). Although the 
rate-limiting step in non-erythroid cells is the delta-
aminolevulinate formation, in erythroid cells, the 
rate-limiting step is acquisition of iron to mitochon-
dria. ABCB6 (ABCB Member 6), a protein very simi-
lar to ABCB7, has been shown to localize at the 
outer mitochondrial membrane [45]. A recent study 
suggested that ABCB6 is upregulated by elevation of 
cellular porphyrins and has a function in porphyrin 
transport to mitochondria. The authors also pre-
dicted that ABCB6 is functionally linked to heme 
biosynthesis [46]. 
Mitochondrial disorders related to iron metabolism
The current understanding of mitochondrial iron 
metabolism has led to elucidation of pathophysio-
logic mechanisms in some disorders (Table 4). 
These disorders usually affect erythroid cells as well 
as neural tissues. 
Friedreich ataxia
Friedreich ataxia (FRDA) is the most common 
form of autosomal recessive ataxia. The disease is 
characterized by progressive ataxia of all limbs, skel-
etal and cardiac muscle myopathy, skeletal deformi-
ties, impaired glucose tolerance or diabetes mellitus, 
sensorineural deafness, and optic neuropathy [47]. 
The molecular abnormality in more than 97% of 
patients is GAA trinucleotide repeat expansion in 
intron 1 of the FXN gene [48]. Normal alleles of the 
FXN gene have 5 to 30 GAA repeat expansions; how-
ever, disease alleles have from 70 to more than 1,000 
GAA triplets. Increased GAA repeats causes triplex 
DNA structures, called “sticky DNA”, which interfere 
with FXN-mRNA transcription [49]. As in other triplet 
repeat disorders, the size of triplet expansion corre-
lates inversely with the age of onset and directly with 
the rate of disease progression [50]. 
Since known mitochondrial diseases and FRDA 
share some clinical manifestations, mitochondrial 
disturbance in the etiology of FRDA has long been 
suspected. For example, isolated vitamin A deficien-
cy, a disease with mitochondrial involvement, has 
strikingly similar signs and symptoms with FRDA [51]. 
After demonstration of a yeast that has mitochondrial 
iron accumulation due to a defective protein homo-
log with FTX, subsequent studies revealed defective 
FTX in the etiology of FRDA [52]. FTX plays a vital role 
in the regulation of mitochondrial iron metabolism. 
However, the pathophysiology of FRDA has not been 
completely understood to date. Oxidative stress due 
to FTX deficiency has usually been cited in the FRDA 
pathophysiology. The decrease in the ISC-containing 
proteins (aconitase and mitochondrial respiratory 
chain complexes) observed in heart biopsies of 
patients with FRDA supports that this finding was 
related to a mitochondrial damage caused by iron 
overload [53]. Another study on cultured fibroblasts 
carrying homozygous FRDA mutation showed that 
these fibroblasts were more sensitive to oxidative 
stress than were the controls [54]. Treatment with 
deferoxamine and apoptosis inhibitors rescued fibro-
blasts with FRDA mutation. A recent study that dem-
onstrated upregulation of stress pathways in FTX-
deficient cells further supports the role of oxidative 
stress in FRDA as well [55]. 
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X-linked sideroblastic anemia (XLSA) is a rare 
disorder caused by mutations in the ALAS2 gene 
[56]. The peripheral smear of patients typically 
includes two distinct erythrocyte populations: nor-
mochromic normocytic erythrocytes together with 
hypochromic microcytic cells. Bone marrow exam-
ination reveals ringed sideroblasts due to increased 
iron within mitochondrial ferritin [57]. Since neuro-
nal cells rely on ALAS1 for iron metabolism, no 
neurological finding is present in these patients in 
contrast with XLSA with ataxia. Although the inheri-
tance is X-linked recessive, some female carriers 
may present with severe anemia. This finding is 
attributed to an additional event following inheri-
tance of the ALAS2 mutation, i.e. congenital skew-
ing led to dominance of hematopoietic cells express-
ing the X chromosome with the mutant gene [58]. 
Interestingly, a case study revealed a significantly 
higher frequency of coinheritance of HFE mutant 
allele C282Y in patients with XLSA compared to the 
normal population [57]. Interaction of two mutant 
alleles may point out the severity of iron overload. 
Response to pyridoxine treatment is variable among 
XLSA patients. This study [57] also revealed that 
iron overload suppressed response to pyridoxine. 
Another factor suggested for variability in pyridoxine 
response is the location of the mutation on the 
ALAS2 gene. Analysis of the ALAS2 crystal structure 
in a recent study revealed that patients with muta-
tions close to the 5’ pyridoxal phosphate binding 
site respond to pyridoxine [59]. 
Pyridoxine-unresponsive sideroblastic anemia due to 
GLRX5 mutation
In 2007, a 60-year-old southern Italian man who 
presented with severe microcytic anemia, jaundice, 
hepatosplenomegaly, iron overload, ringed sidero-
blasts, and cirrhosis was reported [60]. His unaf-
fected parents were consanguineous, consistent 
with autosomal recessive inheritance. Interestingly, 
anemia of the patient worsened with transfusion 
but improved with iron chelation. Striking similari-
ties of his phenotype with mutant shiraz zebrafish 
directed the authors to the Glutaredoxin 5 (GLRX5) 
gene, which was largely deleted in shiraz zebrafish. 
They found a homozygous mutation in this gene 
that interferes with intron 1 splicing and causes a 
drastic reduction in GLRX5-RNA. GLRX5 deficiency 
causes impaired ISC synthesis that activates cyto-
solic IRP1 and finally leads to increased cellular iron 
import. As discussed above, increased IRP1 results 
in increased TfR and decreased ferritin and ALAS2 
synthesis. As a result, decreased ALAS2 level causes 
anemia in spite of increased intracellular iron level. 
In this low-heme environment, IRP2 does not under-
go proteosomal degradation. Prolonged activity of 
IRP2 may contribute to increased mitochondrial 
iron. The authors concluded that redistribution of 
iron into cytoplasm by iron chelation might relieve 
iron excess, improving heme synthesis and anemia. 
X-linked sideroblastic anemia with ataxia
X-linked sideroblastic anemia with ataxia is a 
mitochondrial disease caused by a mutation in the 
nuclear genome. The disease is characterized by 
hypochromic microcytic anemia with ring sidero-
blasts and early onset, nonprogressive spinocerebel-
lar ataxia. Missense mutations on the ABCB7 gene 
cause partial loss of function in patients with this dis-
ease [61]. Nonsense mutations have not been identi-
fied, possibly due to the lethal effect of complete loss 
of function that was shown in a knock out mouse 
model [62]. The defect in the ABCB7 gene causes 
deficiency in ISCs in cytoplasm but not in mitochon-
dria. However, iron is accumulated within mitochon-
dria by an unknown mechanism [43]. 
Myopathy associated with ISCU1 defect
The disease was first described in patients from 
Sweden and characterized by low physical perfor-
mance. Physical activity results in early fatigue, dys-
pnea, and palpitations followed by hard and tender 
muscles and muscle cramps. Recently, a splice 
mutation in the ISC scaffold protein ISCU has been 
reported in these patients [63]. The loss of FTX in 
FRDA and GLRX5 in pyridoxine-unresponsive sid-
eroblastic anemia causes deficiency in ISCs as in 
the myopathy associated with ISCU1 defect. 
Typically, iron accumulation in mitochondria is a 
common event in these three disorders. The authors 
suggested that this observation supported the pos-
sibility that one or more ISC proteins act as sensor 
for regulation of mitochondrial iron homeostasis.
GRACILE syndrome
GRACILE syndrome (Growth Retardation, Amino 
aciduria, Cholestasis, Iron overload, Lactic acidosis, 
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neonates from Finland [64]. Necropsy findings have 
revealed increased liver iron content, paucity of 
intrahepatic bile ducts and periportal fibrosis in the 
oldest patient, who died at the age of 4 months. 
Electron microscopic studies revealed an abun-
dance of hemosiderin granules; however, the num-
ber and structure of mitochondria were normal. 
Subsequently, case reports including Turkish 
patients together with patients from other countries 
have been followed [65]. Distinctive clinical find-
ings were reported among patients from different 
countries: Turkish and British patients had variable 
neurological symptoms and findings. Recently, 
mutations in the BCS1L gene as a cause of this dis-
order have been identified [66]. This gene encodes 
a mitochondrial inner-membrane protein. It is a 
chaperone that is presumed to facilitate insertion of 
Rieske Fe/S protein into precursors of mitochondrial 
respiratory chain complex III. The Rieske iron-sulfur 
protein is a nuclear-encoded subunit of the mam-
malian cytochrome complex III of the mitochondri-
al respiratory chain [67]. Interestingly, the British 
and Turkish patients with GRACILE syndrome had 
mitochondrial complex III deficiency, whereas in 
the Finnish patients, complex III activity was within 
the normal range. Also, a distinctive mutation in the 
BCS1L gene has been found in Turkish patients.
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